Aligos Therapeutics (ALGS) Set to Announce Quarterly Earnings on Tuesday

Aligos Therapeutics (NASDAQ:ALGS) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Aligos Therapeutics to post earnings of ($0.19) per share for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $2.68 million for the quarter, compared to analyst estimates of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative return on equity of 116.41%. On average, analysts expect Aligos Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock traded up $0.01 during trading hours on Wednesday, hitting $0.78. The company had a trading volume of 27,452 shares, compared to its average volume of 343,145. The firm has a market capitalization of $59.01 million, a P/E ratio of -0.49 and a beta of 2.34. The firm’s fifty day moving average is $0.91 and its 200-day moving average is $0.76. Aligos Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.38.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).